

Human Acyl-CoA: Cholesterol Acyltransferase (hACAT) Inhibitory Activities of Triterpenoids from Roots of *Glycine max* (L.) Merr.

Jin Hwan Lee, Young Bae Ryu, Byong Won Lee, Jin Hyo Kim, Woo Song Lee,[†] Yong-Dae Park,[†] Tae-Sook Jeong,[†] and Ki Hun Park*

Division of Applied Life Science (BK21 Program), EB-NCRC, Institute of Agriculture & Life Science, Graduate School of Gyeongsang National University, Jinju 660-701, Korea. *E-mail: khpark@gsnu.ac.kr

[†]National Research Laboratory of Lipid Metabolism & Atherosclerosis, Korea Research Institute of Bioscience and Biotechnology, Daejeon 305-806, Korea

Received January 9, 2008

Eight triterpenoids, six lanostanes **1-6**, one lupenane **7**, and one oleanane **8**, were isolated by bioactivity-guided fractionation of the ethylacetate extract from roots of *Glycine max* (L.) Merr. All isolated compounds were examined for their inhibitory activities against human ACAT-1 (hACAT-1) and human ACAT-2 (hACAT-2). Among them, three triterpenoids showed potent hACAT inhibitory activities, (24*R*)-ethylcholest-5-ene-3,7-diol (**1**) and 3 β -hydroxylup-20(29)-en-28-oic acid (**7**) exhibited more potent inhibitory activity against hACAT-1 (**1**: IC₅₀ = 25.0 \pm 1.2 and **7**: IC₅₀ = 11.5 \pm 0.4 μ M) than hACAT-2 (**1**: IC₅₀ = 102.0 \pm 5.4 and **7**: IC₅₀ = 33.9 \pm 3.7 μ M), respectively. Interestingly, 5 α ,8 α -epidioxy-24(*R*)-methylcholesta-6,22-diene-3 β -ol (**4**) has proven to be a specific inhibitor against hACAT-1 (IC₅₀ = 38.7 \pm 0.8 μ M) compared to hACAT-2 (IC₅₀ > 200). In conclusion, this is the first study to demonstrate that triterpenoids of *G. max* have potent inhibitory activities against hACAT-1 and hACAT-2.

Key Words : *Glycine max*, Root, Human acyl-CoA: cholesterol acyltransferase (hACAT), Triterpenoid, Atherosclerosis

Introduction

Acyl-CoA: cholesterol acyltransferase (ACAT, E.C. 2.3.1.26) is an allosteric enzyme that catalyzes the acylation of cholesterol to cholesteryl esters with long chain fatty acids, which is a very attractive target for the prevention and treatment of cardiovascular diseases and hypercholesterolemia.¹⁻³ In mammalian species, two isoforms such as ACAT-1 and ACAT-2 exhibited different tissue distribution and membrane.^{4,5} In humans, ACAT-1 performs a critical role in the formation of macrophage foam cells, whereas ACAT-2 is in charge of the cholesterol absorption process in intestinal enterocytes.^{6,7} Therefore, ACAT inhibitors are being investigated as potent therapeutic agents in the treatment of both atherosclerosis and hypercholesterolemia.⁸ In our search for ACAT inhibitors from natural sources, we found that the EtOAc extract of *Glycine max* (L.) Merr. roots exhibited inhibitory activities against hACAT-1 and hACAT-2 with 82% and 59% inhibition at 100 μ g/mL, respectively.

Soybeans (*G. max*) are one of the most produced and commercialized commodities worldwide with not only high amounts of protein and oil but also several phytochemicals.⁹⁻¹² It is well established that isoflavones are responsible for the biological activities of soybean.¹³ Even though researchers mainly have focused on secondary metabolites of soybean because of their potential medicinal values including antioxidant,¹⁴ anticancer,¹⁵ and antiatherosclerotic activities,¹⁶ their application concerning ACAT inhibitor has so far not been reported. Recently, we were the first to report evaluation of low-density lipoprotein (LDL)-

antioxidant pterocarpan concerning atherosclerosis from this species.¹⁷ In this study, the isolation of phytochemicals from *G. max*, bioactivity-guided fractionations, using hACAT inhibitory activity measurements led to the isolation of three potent hACAT inhibitors **1**, **4**, and **7** as well as five triterpenoids. Moreover here, we describe the isolation, structure characterization, and hACAT inhibitory activities.

Results and Discussion

The methanolic extract of the dried roots of *G. max* showed a strong inhibition upon hACAT. Solvent partition of the methanolic extract resulted in the localization of the active compounds in EtOAc-soluble fraction. Further bioactivity-guided fractionation of combined EtOAc fraction using hACAT inhibitory activity, yielded eight triterpenoids isolated by repeated column chromatography, Sephadex LH-20, and recrystallization. These compounds **1-8** were identified as (24*R*)-ethylcholest-5-ene-3,7-diol (**1**), (24*R*)-ethylcholest-5-en-3-ol-7-one (**2**), (24*R*)-ethylcholestane-3,7-diol (**3**), 5 α ,8 α -epidioxy-24(*R*)-methylcholesta-6,22-diene-3 β -ol (**4**), 24(*R*)-methylcholesta-5,7,22-tiene-3-ol (**5**), 17-acetoxy-4,4-dimethyl-24-methylene-5-cholesta-8,14-diene-3,11-diol (**6**), 3 β -hydroxylup-20(29)-en-28-oic acid (**7**), and 12-oleanene-3 β ,22 β ,3,22,24-triol (**8**), respectively, by analyses of spectroscopic data and comparison of their physical data previously reported (Figure 1).¹⁸⁻²⁸ Among them, three compounds **4**, **7**, and **8** could be obtained in gram amount (**4**: 1.9 g, **7**: 1.1 g, and **8**: 2.1 g, respectively) as the dominant triterpenoids constituents. Moreover, five




Figure 1. Chemical structures of isolated triterpenoids **1-8** from roots of *G. max*.

compounds **1**, **2**, **4**, **5**, and **7** were first isolated from this plant.

Although a large number of reports have been issued on the biological activities of *G. max*, there is no report on the component of soybean which inhibits hACAT. The isolated triterpenoids **1-8** from *G. max* roots have been evaluated for the first time for their inhibitory activities on hACAT-1 and hACAT-2 for the development of useful antiatherogenic and

hyperchole-sterolemic substances. The rate of incorporation of [14 C] oleoyl-CoA into cholesteryl ester was determined using the expressed hACAT-1 and hACAT-2 from Hi5 cells and oleic acid anilide was used as positive control.²⁹ As shown in Table 1, three triterpenoids **1**, **4**, and **7** showed potent hACAT inhibitory activities, whereas the other compounds exhibited a very weak or no inhibitory activities. The compounds **1**, **4**, and **7** were detected to inhibit hACAT-1 and hACAT-2 activities in a dose-dependent manner with significant hACAT inhibitory effects observed at 10–100 μ M (Figure 2).

(24*R*)-Ethylcholest-5-ene-3,7-diol (**1**) of lanostane-type triterpenoid inhibited hACAT-1 with IC_{50} values of 25.0 ± 1.2 μ M as well as hACAT-2 with IC_{50} values of 102.0 ± 5.4 μ M (Table 1). Among other lanostane-type triterpenoids, 5 α ,8 α -epidioxy-24(*R*)-methylcholesta-6,22-diene-3 β -ol (**4**) exhibited relatively high hACAT-1 inhibitory activity with IC_{50} value of 38.7 ± 0.8 μ M, although inhibition of the hACAT-2 activity was barely detected (> 200 μ M). Allyl alcohol group in B-ring of lanostane skeleton may play a role as a key functionality for inhibitory activity on hACAT. Because compound **1** has allyl alcohol in B-ring apparently




Figure 2. Effect of triterpenoids **1**, **4**, and **7** on hACAT-1 (A) and hACAT-2 (B) inhibitory activities.

Table 1. Human ACAT inhibitory activities of triterpenoids **1-8**

Compound	IC_{50} (μ M) values ^a	
	hACAT-1	hACAT-2
1	25.0 ± 1.2	102.0 ± 5.4
2	NI ^c	NI
3	NI	NI
4	38.7 ± 0.8	> 200
5	23% ^b	NI
6	7%	4%
7	11.5 ± 0.4	33.9 ± 3.7
8	37%	9%

^a*In vitro* ACAT inhibitory activity was measured using expressed hACAT-1, and hACAT-2. Data are shown as mean values of three independent experiments performed in triplicate (Mean \pm S.D., $n = 3$).

^bPercentage at 25 μ M. ^cNI: no inhibition.

and compound **4** has 1,2-dioxinyl group that could be transformed to allyl alcohol functionality in aqueous condition easily. In lupenane-type triterpenoids, 3 β -hydroxylup-20(29)-en-28-oic acid (**7**) showed the most potent inhibitory activities against both hACAT-1 and hACAT-2 with IC₅₀ values of 11.5 ± 0.4 and 33.9 ± 3.7 μ M, respectively, which was in accordance with our previous report.³⁰ This result suggested that lanostane-type triterpenoids **1** and **4** and lupenane-type triterpenoids **7** in soybean could be expected as hACAT inhibitors.

Experimental Section

General Experimental Procedures. Melting points were measured on a Thomas Scientific capillary melting point apparatus (Electrothermal 9300, UK) and are uncorrected. IR spectra were recorded on a Bruker IFS66 (Bruker, Karlsruhe, Germany) infrared Fourier transform spectrophotometer (KBr) and ¹H and ¹³C NMR along with 2D NMR data were obtained on a Bruker AM 500 (¹H NMR at 500 MHz, ¹³C NMR at 125 MHz) spectrometer (Bruker, Karlsruhe, Germany) in CDCl₃, pyridine-*d*₆, DMSO-*d*₆, and CD₃OD. Optical rotation values were measured by a Perkin-Elmer 343 polarimeter and [α]_D-values are given in units of 10⁻¹ deg cm²g⁻¹. A scintillation counter was used with 1450 Microbeta Trilux, Qallac Oy (Turku, Finland) for hACAT inhibitory activity. The [1-¹⁴C] oleoyl-CoA (56.0 μ Ci/mmol) solution was purchased from the Amersham Biosciences Korea Ltd. KH₂PO₄, dithiothreitol, bovine serum albumin (fatty acid free) were purchased from the Sigma-Aldrich. All the reagent grade chemicals were purchased from Sigma (Sigma Chemical Co, St. Louis, MO, USA).

Plant Material. The roots of *G. max* (Taekwangkong cultivar) were collected ten days after R8 (full maturity stage) at Moonsan, Jinju, Korea at the end of September 2003. The fresh roots of *G. max* were then dried.

Extraction and Isolation. The dried roots of *G. max* (2.0 kg) were chopped and extracted three times (6 L \times 3) with methanol for 10 days at room temperature. The concentrated methanolic extract (98.0 g) was suspended in H₂O and successively partitioned with *n*-hexane (1.0 L), EtOAc (1.5 L), and *n*-BuOH (1.2 L), which yielded a *n*-hexane (10.4 g), EtOAc (29.8 g), and *n*-BuOH (12.6 g) extracts. The EtOAc extract showed potent inhibitory activities against hACAT-1 and hACAT-2 with 82% and 59% inhibition at 100 μ g/mL, respectively, which was chromatographed on a silica gel (6 \times 60 cm, 230-400 mesh, 680 g), eluting a step gradient of CHCl₃-acetone (25:1 \rightarrow 1:2) to give twelve fractions (F1-F12), based on the comparison of TLC profiles. The active fraction F4 (6.1 g) was submitted to a flash silica gel column chromatography (5.0 \times 60 cm, 580 g, 230-400 mesh), eluted with a step gradient of *n*-hexane-EtOAc (20:1 \rightarrow 1:1). Altogether, 65 subfractions were collected. Among them, subfractions 24-35 (1.7 g) were concentrated and separated by a silica gel column (3.0 \times 50 cm, 190 g, 230-400 mesh) eluting with *n*-hexane-EtOAc gradient (25:1 \rightarrow 6:1) to yield compounds **2** (89 mg) and **5** (74 mg). Subfractions 49-61

Table 2. ¹³C NMR of compounds **1**, **2**, **4**, **5**, and **7** at 125 MHz (ppm, m)^a

Position	Compound				
	1	2	4	5	7
1	37.9 (t)	38.9 (t)	34.7 (t)	38.4 (t)	38.6 (t)
2	31.8 (t)	34.3 (t)	30.1 (t)	32.0 (t)	27.5 (t)
3	65.8 (d)	73.7 (d)	66.4 (d)	70.5 (d)	77.2 (d)
4	39.6 (t)	40.0 (t)	37.0 (t)	40.8 (t)	38.9 (s)
5	146.6 (s)	168.8 (s)	82.2 (s)	141.3 (s)	55.3 (d)
6	124.3 (d)	126.7 (d)	130.7(d)	119.6 (d)	18.3 (t)
7	65.7 (d)	200.8 (s)	135.4 (d)	116.3 (d)	34.3 (t)
8	37.4 (d)	37.5 (d)	79.4 (s)	140.0 (s)	40.6 (s)
9	49.8 (d)	54.0 (d)	51.2 (d)	46.3 (d)	50.3 (d)
10	37.8 (s)	38.4 (s)	37.0 (s)	37.1 (s)	38.0 (s)
11	21.1 (t)	21.4 (t)	23.4 (t)	21.1 (t)	20.8 (t)
12	42.4 (t)	42.9 (t)	39.4 (t)	28.3 (t)	25.5 (t)
13	42.5 (s)	46.2 (s)	44.6 (s)	42.9 (s)	38.6 (d)
14	56.2 (d)	56.4 (d)	51.7 (d)	55.8 (d)	42.4 (s)
15	24.7 (t)	24.5 (t)	20.6 (t)	22.2 (t)	29.3 (t)
16	28.7 (t)	28.6 (t)	28.6(t)	38.4 (t)	32.1 (t)
17	56.1 (d)	56.3 (d)	56.1 (d)	54.6 (d)	55.8 (s)
18	12.0 (q)	12.4 (q)	12.9 (q)	12.1 (q)	47.0 (d)
19	18.6 (q)	19.9 (q)	18.2 (q)	16.3 (q)	48.9 (d)
20	36.5 (d)	36.5 (d)	39.7 (d)	40.4 (d)	150.7 (s)
21	19.2 (q)	19.1 (q)	20.9 (q)	19.7 (q)	30.5 (t)
22	34.3 (t)	34.6 (t)	132.3 (d)	135.6 (d)	36.7 (t)
23	26.4 (t)	26.5 (t)	135.2 (d)	132.0 (d)	28.5 (q)
24	49.8 (d)	51.6 (d)	42.8 (d)	42.9 (d)	16.1 (q)
25	28.7 (t)	29.6 (d)	33.1 (d)	33.1 (d)	16.1 (q)
26	20.2 (q)	20.2 (q)	20.0 (q)	20.0 (q)	16.3 (q)
27	19.4 (q)	19.4 (q)	19.6 (q)	23.0 (q)	14.7 (q)
28	23.5 (t)	23.5 (t)	17.6 (q)	17.6 (q)	177.6 (s)
29	12.4 (q)	12.4 (q)			109.9 (t)
30					19.3 (q)

^aThe chemical shifts of compounds **1**, **2**, **4**, and **5** were determined in CDCl₃, and compound **7** was measured in DMSO-*d*₆.

(1.2 g) were subjected to silica gel column chromatography (3.0 \times 50 cm, 150 g, 230-400 mesh) with *n*-hexane-acetone (15:1 \rightarrow 4:1) and then purified by a second silica gel column (2.5 \times 50 cm, 110 g, 230-400 mesh) using a gradient of *n*-hexane-acetone (16:1 \rightarrow 4:1) to obtain compounds **1** (29 mg) and **3** (23 mg). The active fractions F8-9 (5.9 g) were applied to silica gel column chromatography (5.0 \times 60 cm, 520 g, 230-400 mesh) by eluting initially with CHCl₃, then with CHCl₃-acetone mixture of increasing polarity (25:1 \rightarrow 1:1), resulting in 78 subfractions. Subfractions 13-29 (1.9 g) were evaporated and further purified in small chromatographic column containing silica gel, eluting with CHCl₃-acetone (20:1 \rightarrow 8:1) to yield the pure compound **4** (1.4 g) as a white powder. Also, subfractions 38-43 (1.5 g) were pooled and rechromatographed on silica gel (3.5 \times 50 cm, 180 g, 230-400 mesh) with CHCl₃-acetone (16:1 \rightarrow 3:1) to give compound **8** (2.1 g). Subfractions 55-65 (1.3 g) were evaporated and recrystallized from CHCl₃-acetone mixture to give compound **7** (1.1 g). Subfraction 70-75 (675 mg)

were concentrated and submitted to a silica gel column chromatography (2.5 × 50 cm, 130 g, 230-400 mesh) eluting with CHCl₃-acetone (10:1 → 1:1) and rechromatographed on a Sephadex LH-20 (1.5 × 50 cm) for elution with methanol in order to yield compound **6** (39 mg). The spectroscopic data of five isolated triterpenoids were described as follows and the other compounds were described as previously reported.¹⁸

Compound 1: White powder, mp 179-181 °C, $[\alpha]_D^{20} +32.7^\circ$ (*c* 0.44, CH₃OH); IR (KBr): 3460, 1712 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.62 (3H, s, H-18), 0.63 (3H, s, H-19), 0.75 (3H, s, H-29), 0.76 (3H, d, *J* = 6.8 Hz, H-21), 0.85 (3H, d, *J* = 6.4 Hz, H-27), 0.87 (3H, d, *J* = 6.4 Hz, H-26), 0.93 (1H, m, H-24), 1.09 (1H, m, H-17), 1.10 (1H, m, H-14), 1.11 (1H, m, H-1β), 1.39 (1H, m, H-8), 1.40 (1H, m, H-9), 1.78 (1H, m, H-1α), 1.95 (2H, m, H-4), 2.17 (2H, m, H-15), 2.27 (2H, m, H-12), 2.36 (1H, m, H-28α), 2.37 (2H, m, H-23), 2.39 (2H, m, H-16), 2.41 (1H, m, H-20), 2.38 (1H, m, H-11α), 2.43 (1H, m, H-28β), 2.50 (2H, m, H-22), 2.56 (1H, m, H-11β), 2.60 (1H, m, H-25), 2.83 (1H, m, H-2α), 3.19 (1H, m, H-2β), 3.52 (1H, m, H-3), 3.78 (1H, s, H-7), and 5.54 (1H, d, *J* = 5.1 Hz, H-6). ¹³C NMR (125 MHz, CDCl₃): see Table 2.

Compound 2: Whiter powder; mp 140-142 °C, $[\alpha]_D^{20} -3.9^\circ$ (*c* 0.62, CHCl₃); IR (KBr): 3400, 1640 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.61 (3H, s, H-18), 0.75 (3H, d, *J* = 6.7 Hz, H-26), 0.76 (3H, d, *J* = 7.0 Hz, H-27), 0.77 (3H, t, *J* = 9.3 Hz, H-29), 0.83-0.89 (1H, m, H-24), 0.83-0.86 (1H, m, H-9), 0.85 (3H, d, *J* = 6.4 Hz, H-21), 0.89-0.93 (1H, m, H-14), 0.94 (3H, s, H-19), 0.91-1.01 (1H, m, H-15α), 0.95-1.05 (1H, m, H-1α), 0.99-1.08 (1H, m, H-17), 1.06-1.12 (2H, m, H-23), 1.06-1.12 (1H, m, H-12α), 1.10 (2H, m, H-22), 1.15-1.21 (2H, m, H-28), 1.16-1.19 (1H, m, H-16α), 1.18 (1H, m, H-25), 1.24-1.30 (1H, m, H-20), 1.37-1.41 (1H, m, H-8), 1.37-1.44 (2H, m, H-11), 1.48-1.53 (1H, m, H-15β), 1.75-1.81 (1H, m, H-1β), 1.75-1.79 (2H, m, H-2), 1.77 (1H, m, H-16β), 1.88-1.95 (1H, m, H-12β), 2.17 (1H, ddd, *J* = 11.4, 4.9, 2.0 Hz, H-4α), 2.21 (1H, ddd, *J* = 13.1, 4.9, 2.0 Hz, H-4β), 3.41-3.45 (1H, m, H-3), 5.28 (1H, dd, *J* = 2.6, 5.2 Hz, H-6). ¹³C NMR (125 MHz, CDCl₃): see Table 2.

Compound 4: Amorphous white powder, mp 178-179 °C, $[\alpha]_D^{20} -25.4^\circ$ (*c* 1.00, CHCl₃); IR (KBr): 3400, 1459 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.10 (3H, d, *J* = 11.0 Hz, H-21), 0.79 (3H, d, *J* = 7.6 Hz, H-27), 0.81 (3H, d, *J* = 7.6 Hz, H-26), 0.82 (3H, s, H-18), 0.88 (3H, s, H-19), 0.91 (3H, d, *J* = 11.4 Hz, H-28), 1.22 (1H, m, H-17), 1.22 (1H, m, H-11α), 1.24 (1H, m, H-12α), 1.38 (1H, m, H-15α), 1.40 (1H, m, H-16α), 1.47 (1H, m, H-25), 1.48 (1H, s, H-9), 1.50 (1H, m, H-11β), 1.53 (1H, m, H-2α), 1.55 (1H, m, H-14), 1.59 (1H, m, H-15β), 1.67 (1H, m, H-1α), 1.75 (1H, m, H-16β), 1.84 (1H, m, H-2β), 1.85 (1H, m, H-24), 1.90 (1H, m, H-4β), 1.94 (1H, m, H-1β), 1.95 (1H, m, H-12β), 2.03 (1H, m, H-20), 2.09 (1H, m, H-4α), 3.96 (1H, m, H-3), 5.13 (1H, dd, *J* = 15.2, 7.7 Hz, H-23), 5.23 (1H, dd, *J* = 15.2, 7.7 Hz, H-22), 6.23 (1H, d, *J* = 8.6 Hz, H-7), and 6.49 (1H, d, *J* = 8.6 Hz, H-6). ¹³C NMR (125 MHz, CDCl₃): see Table 2.

Compound 5: White powder, mp 165-167 °C, $[\alpha]_D^{20}$

-130° (*c* 0.80, CHCl₃); IR (KBr): 3450, 1565 cm⁻¹; ¹H NMR (500 MHz, CDCl₃) δ 0.65 (3H, s, H-18), 0.84 (3H, d, *J* = 7.6 Hz, H-26), 0.86 (3H, d, *J* = 7.6 Hz, H-27), 0.93 (3H, d, *J* = 11.4 Hz, H-28), 0.96 (3H, s, H-19), 1.05 (3H, d, *J* = 11.0 Hz, H-21), 1.15 (2H, m, H-12), 1.26 (1H, m, H-14), 1.27 (1H, m, H-1β), 1.46 (2H, m, H-15), 1.47 (2H, m, H-11), 1.48 (1H, m, H-25), 1.64 (2H, m, H-2), 1.66 (1H, m, H-16α), 1.66 (1H, m, H-1α), 1.75 (1H, s, H-9), 1.77 (1H, m, H-17), 1.78 (1H, m, H-20), 1.79 (1H, m, H-24), 1.99 (1H, m, H-16β), 2.29 (1H, m, H-4β), 2.46 (1H, m, H-4α), 3.65 (1H, m, H-3), 5.21 (2H, m, H-22 and H-23), 5.40 (1H, m, H-7), and 5.59 (1H, dd, *J* = 4.0, 9.3 Hz, H-6). ¹³C NMR (125 MHz, CDCl₃): see Table 2.

Compound 7: White needles, mp 307-309 °C, $[\alpha]_D^{20} +7.6^\circ$ (*c* 1.00, pyridine); IR (KBr): 3450, 1689 cm⁻¹; ¹H NMR (500 MHz, CD₃OD) δ 0.54 (1H, s, H-5), 0.56 (3H, s, H-24), 0.68 (3H, s, H-25), 0.78 (3H, s, H-23), 0.78 (3H, s, H-26), 0.84 (3H, s, H-27), 0.99 (1H, m, H-12α), 1.01 (2H, m, H-15), 1.15 (1H, m, H-11α), 1.15 (1H, m, H-9), 1.21 (1H, m, H-6α), 1.22 (2H, m, H-7), 1.29 (1H, m, H-11β), 1.26 (1H, m, H-16α), 1.35 (2H, m, H-2), 1.37 (1H, m, H-6β), 1.42 (1H, m, H-18), 1.48 (1H, m, H-1β), 1.51 (1H, m, H-1α), 1.56 (1H, m, H-12β), 1.56 (3H, s, H-30), 1.70 (2H, m, H-22), 1.71 (2H, m, H-21), 2.13 (1H, m, H-16β), 2.14 (1H, m, H-13), 2.86 (1H, m, H-19), 2.88 (1H, m, H-3), 4.47 (1H, d, *J* = 2.1 Hz, H-29α), and 4.60 (1H, d, *J* = 2.1 Hz, H-29β). ¹³C NMR (125 MHz, CD₃OD): see Table 2.

Inhibitory Activity against hACAT. The microsomal fractions of Hi5 cells containing baculovirally expressed hACAT-1 and hACAT-2 were used as sources of the enzyme.²⁹ The inhibitory activities of hACAT-1 and hACAT-2 were determined as previously described with some slight modifications.^{18,31} Briefly, the reaction mixture, which contained 4 μL of microsomes (8 mg/mL protein) and 20 μL of KH₂PO₄ buffer (0.5 M, pH 7.4) with 10 mM dithiothreitol, 15 μL of bovine serum albumin (BSA, fatty acid free, 40 mg/mL), 2 μL of cholesterol in acetone (20 μg/mL), 41 μL of water, and 10 μL of test compound in a total volume of 92 μL. The tube containing the reaction mixture was incubated for 20 min in a shaking water bath set at 37 °C. After adding 8 μL of [1-¹⁴C] oleoyl-CoA solution (56.0 μCi/mmol, final con. 10 μM), the tube was vortexed and then placed back into the water bath for 25 min at 37 °C. To stop the reaction mixture, 1.0 mL of isopropanol-heptane (4:1; v/v) solution was added to the tube. A solution mixture of 0.6 mL heptane and 0.4 mL potassium phosphate buffer (0.1 M, pH 7.4) with 2 mM dithiothreitol was added to the terminated reaction mixture. After centrifugation for 2 min, cholesterol oleate was recovered in the upper phase (total volume 0.9-1.0 mL). The radioactivity in 100 μL of the upper layer was measured in a 3 mL liquid scintillation vial with 3 mL of scintillation cocktail (Lipoluma, Lumac Co.) using a liquid scintillation counter (1450 Micrombeta Trilux Wallac Oy, Turku, Finland). Background values were obtained by preparing heat inactivated microsomes or normal insect cell lysate microsomes, usually background value was 200-250 cpm, at 8000 cpm of the ACAT reaction. ACAT activity was expressed as a

defined unit, cholesteryl oleate pmol/min/mg protein. The hACAT inhibitory activities of the isolated compounds were confirmed by the positive control with oleic acid anilide, which inhibited hACAT-1 and hACAT-2 with IC₅₀ values of 0.14 and 0.17 μ M, respectively.²⁹

In conclusion, we reported eight triterpenoids **1-8** isolated from roots of *G. max* and examined their hACAT inhibitory activities. Especially, three triterpenoids **1**, **4**, and **7** exhibited high inhibitory activities against hACAT-1 (**1**: 25.0 \pm 1.2, **4**: 38.7 \pm 0.8, and **7**: 11.5 \pm 0.4 μ M, respectively) and hACAT-2 (**1**: 102.0 \pm 5.4, **4**: > 200, and **7**: 33.9 \pm 3.7 μ M, respectively). This is nevertheless the first report to demonstrate that triterpenoids of *G. max* showed potent inhibitory activities against hACAT-1 and hACAT-2. Further studies on hACAT inhibitory activity for the treatment of hypercholesterolemia and atherosclerosis are under investigation.

Acknowledgements. This work is supported by a Grant (BioGreen 21 project) from the Rural Development Administration, Korea. Young Bae Ryu was supported by a grant from the BK21 program, the Ministry of Education and Human Resources Development, Korea.

Supporting Information Available: ¹H, ¹³C, and 2D NMR of compounds **1-8**; EIMS of compounds **3**, **4**, and **7**; X-ray crystal structure analysis of compound **5**. This material is available via the internet at <http://www.kcsnet.or.kr>.

References

1. Chang, T. Y.; Chang, C. C. Y.; Cheng, D. *Annu. Rev. Biochem.* **1997**, *66*, 613.
2. Ohgami, N.; Kuniyasu, A.; Furukawa, K.; Miyazaki, A.; Hakamata, H.; Horiuchi, S.; Nakayama, H. *Biochem. Biophys. Res. Commun.* **2000**, *277*, 412.
3. Doshi, R.; Wu, J.; Fischelevich, R.; Rodriguez, A. *Expert. Opin. Ther. Patents* **2001**, *11*, 1655.
4. Joyce, C. W.; Shelness, G. S.; Davis, M. A.; Lee, R. G.; Skinner, K.; Anderson, R. A.; Rudel, L. L. *Mol. Biol. Cell* **2000**, *11*, 3675.
5. Lee, R. G.; Willingham, M. C.; Davis, M. A.; Skinner, K. A.; Rudel, L. L. *J. Lipid Res.* **2000**, *41*, 1991.
6. Rudel, L. I.; Lee, R. G.; Cockman, T. L. *Curr. Opin. Lipidol.* **2001**, *12*, 121.
7. Chang, T. Y.; Chang, C. C.; Lin, S.; Yu, C.; Li, B. L.; Miyazaki, A. *Curr. Opin. Lipidol.* **2001**, *12*, 289.
8. Giovannoni, M. P.; Piaz, V. D.; Vergelli, C.; Barlocco, D. *Mini-Rev. Med. Chem.* **2003**, *3*, 576.
9. Merz-Demlow, B.; Duncan, A.; Wangen, K.; Xu, X.; Carr, T.; Phippos, W.; Kurzer, M. *Am. J. Chin. Nutr.* **2000**, *71*, 1462.
10. Charron, C. S.; Allen, F. L.; Johnson, R. D.; Pantalone, V. R.; Sams, C. E. *J. Agric. Food Chem.* **2005**, *53*, 7128.
11. Yamaya, A.; Endo, Y.; Fujimoto, K.; Kitamura, K. *Food Chem.* **2007**, *102*, 1071.
12. Lee, J. H.; Baek, I. Y.; Ko, J. M.; Kang, N. S.; Kim, H. T.; Han, W. Y.; Shin, S. D.; Park, K. Y.; Oh, K. W.; Ha, T. J.; Park, K. H. *J. Appl. Biol. Chem.* **2007**, *50*, 63.
13. Tikkanen, M. J.; Wahala, K.; Ojala, S.; Vihma, V.; Adlercreutz, H. *Proc. Natl. Acad. Sci. U.S.A.* **1998**, *95*, 3106.
14. Lee, C. H.; Yang, L.; Xu, J. Z.; Yeung, S. Y. V.; Huang, Y.; Chen, Z. Y. *Food Chem.* **2005**, *90*, 735.
15. Hendrich, S.; Lee, K. W.; Xu, X.; Wang, H. J.; Murphy, P. A. *J. Nutr.* **1994**, *124*, 1789S.
16. Anthony, M. S.; Clarkson, T. B.; Hughes, C. L.; Morgan, T. M.; Burke, G. L. *J. Nutr.* **1996**, *126*, 43.
17. Lee, J. H.; Lee, B. W.; Kim, J. H.; Jeong, T. S.; Kim, M. J.; Lee, W. S.; Park, K. H. *J. Agric. Food Chem.* **2006**, *54*, 2057.
18. Lee, J. H.; Seo, K. I.; Kang, N. S.; Yang, M. S.; Park, K. H. *Agric. Chem. Biotechnol.* **2006**, *49*, 51.
19. Kvasnica, M.; Sarek, J.; Klinotova, E.; Dzubak, P.; Hajdich, M. *Bioorg. Med. Chem.* **2005**, *13*, 3447.
20. Zhou, W. X.; Nes, W. D. *Tetrahedron Lett.* **2000**, *41*, 2791.
21. Zhang, Y.; Mills, G. L.; Nair, M. G. *J. Agric. Food Chem.* **2002**, *50*, 7581.
22. Singh, S. B.; Zink, D. L.; Dombrowski, A. W.; Polishook, J. D.; Ondeyka, J. G.; Hirshfield, J.; Felock, P.; Hazuda, D. J. *Bioorg. Med. Chem.* **2003**, *11*, 1577.
23. Sasaki, K.; Minowa, N.; Kuzuhara, H.; Nishiyama, S.; Omoto, S. *Tetrahedron Lett.* **1997**, *38*, 8335.
24. Nam, K. S.; Jo, Y. S.; Kim, Y. H.; Hyun, J. W.; Kim, H. W. *Life Sci.* **2001**, *69*, 229.
25. Macías, F. A.; Chinchilla, N.; Varela, R. M.; Molinillo, J. M. G. *Steroids* **2006**, *71*, 603.
26. Kim, S. W.; Park, S. S.; Min, T. J.; Yu, K. H. *Bull. Korean Chem. Soc.* **1999**, *20*, 819.
27. Chung, I. M.; Park, H. Y.; Ali, M.; San, K. Y.; Peebles, C. A. M.; Hong, S. B.; Ahmad, A. *Bull. Korean Chem. Soc.* **2007**, *28*, 229.
28. Hu, H. B.; Zheng, X. D.; Hu, H. S.; Jian, Y. E. *Bull. Korean Chem. Soc.* **2007**, *28*, 1519.
29. Cho, K. H.; An, S.; Lee, W. S.; Paik, Y. K.; Kim, Y. K.; Jeong, T. S. *Biochem. Biophys. Res. Commun.* **2003**, *309*, 864.
30. Lee, W. S.; Im, K. R.; Park, Y. D.; Sung, N. D.; Jeong, T. S. *Biol. Pharm. Bull.* **2006**, *29*, 382.
31. Lee, C. H.; Jeong, T. S.; Choi, Y. K.; Hyun, B. W.; Oh, G. T.; Kim, E. H.; Kim, J. R.; Han, J. I.; Bok, S. H. *Biochem. Biophys. Res. Commun.* **2001**, *284*, 681.